Brand/Development name: nab-docetaxel
Principal Therapy Area: Cancer
ABI-008 is an albumin-bound form of docetaxel, an oncology drug that is marketed by sanofi-aventis as Taxotere. Docetaxel is a mitotic inhibitor; it binds to tubulin and inhibits the disassembly of microtubules, leading to the inhibition of cell division. Along with sanofi-aventis' Taxol (paclitaxel), docetaxel is in the taxane class of drugs.
The proprietary nab (nanoparticle albumin bound) technology on which ABI-008 is based exploits the natural properties of albumin to deliver drugs.
Use this Cancer Drug Futures report to analyse key drivers and dampeners of success
An extensive review of the factors which can affect this product's clinical and commercial performance. Each drug report provides and covers…
What you get
A copy of the Cancer Drug Futures report(s) in print or pdf as you wish
Are you interested in more than one product, indication or therapy area?
Why not build a specific drug futures library and save money!
We appreciate that some customers will need to review many products. That is why, if you buy more than 5 Cancer Drug Futures reports of your choice, we can arrange
Customers focussing on specific disease areas can benefit from buying our cost-effective Cancer Drug Futures collections. Collections are available for the following cancer sectors:
For further information on the products covered, discounts, distribution or a demonstration, please click on the link for email@example.com